NEUROLOGIE PRO PRAXI / Neurol. praxi. 2023;24(5):330-336 / www.neurologiepropraxi.cz 336 HLAVNÍ TÉMA Diagnostické zobrazovací metodyv neuroonkologii FLAIR, 2D FLAIR, and 2D T2-Weighted MR Imaging of Brain Stem Anatomy. AJNR Am J Neuroradiol. 2012;33(5):922-927. 15. Krabbe K, Gideon P, Wagn P, et al. MR diffusion imaging of human intracranial tumours. Neuroradiology. 1997;39(7):483e489. 16. Ku MC, Waiczies S, Niendorf T, Pohlmann A. Assessment of Blood Brain Barrier Leakage with Gadolinium‑Enhanced MRI. Methods Mol Biol. 2018;1718:395-408. doi: 10.1007/978-1-49397531-0_23. PMID: 29341021. 17. Kwock L, Smith JK, Castillo M, et al. Clinical applications of proton MR spectroscopy in oncology. Technol Cancer Res Treat. 2002;1:17-28. 18. Kwong KK, Belliveau JW, Chesler DA, et al. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci U S A. 1992;89:5675-5679. 19. Lee YY, Bruner JM, Van Tassel P, Libshitz HI. Primary central nervous system lymphoma: CT and pathologic correlation. AJR Am J Roentgenol. 1986;147:747-752. 20. Lee YY, Van Tassel P. Intracranial oligodendrogliomas: imaging findings in 35 untreated cases. AJR Am J Roentgenol. 1989;152:361-369. 21. Lin K, Kazmi KS, Law M, Babb J, Peccerelli N, Pramanik BK. Measuring elevated microvascular permeability and predicting hemorrhagic transformation in acute ischemic stroke using first‑pass dynamic perfusion CT imaging. AJNR Am J Neuroradiol. 2007;28:1292-8. 22. Mori S, van Zijl PC. Fiber tracking: principles and strategies - a technical review. NMR Biomed. 2002;15:468-480. 23. Mugler J. Optimized three‐dimensional fast‐spin‐echo MRI. J. Magn. Reson. Imaging. 2014;39(4):745-767. 24. Okamoto K, Ito J, Ishikawa K, et al. Diffusion‑weighted echoplanar MR imaging in differential diagnosis of brain tumors and tumor‑like conditions. Eur Radiol. 2000;10(8):1342e1350. 25. Patel P, Baradaran H, Delgado D, et al. MR perfusion ‑weighted imaging in the evaluation of high‑grade gliomas after treatment: a systematic review and meta‑analysis. Neuro Oncol. 2017;19(1):118-127. doi: 10.1093/neuonc/now148. 26. Pillai JJ. The evolution of clinical functional imaging during the past 2 decades and its current impact on neurosurgical planning. AJNR Am J Neuroradiol. 2010;31:219-225. 27. Price SJ, Jena R, Burnet NG, et al. Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image‑guided biopsy study. AJNR Am J Neuroradiol. 2006;27:1969-1974. 28. Romano A, D‘Andrea G, Minniti G, et al. Pre‑surgical planning and MR‑tractography utility in brain tumour resection. Eur Radiol. 2009;19:2798-2808. 29. Mills SJ, Patankar TA, Haroon HA, et al. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? American Journal of Neuroradiology. 2006;27(4):853-858. 30. Rohde S, Maßberg M, Reinhardt J, et al. Impact of Technical and Morphological Factors on the Precision of Software‑Based MR Tumor Volumetry: a Phantom Study. Rofo. 2008;180(7):654-661. 31. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast‑enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging JMRI. 1999;10:223-232. 32. Toh CH, Chen YL, Hsieh TC, et al. Glioblastoma multiforme with diffusion‑weighted magnetic resonance imaging characteristics mimicking primary brain lymphoma. Case report. J Neurosurg. 2006;105(1):132e135. 33. Ulmer JL, Salvan CV, Mueller WM, et al. The role of diffusion tensor imaging in establishing the proximity of tumor borders to functional brain systems: implications for preoperative risk assessments and postoperative outcomes. Technol Cancer Res Treat. 2004;3:567-576. 34. White ML, Zhang Y, Yu F, Jaffar Kazmi SA. Diffusion tensor MR imaging of cerebral gliomas: evaluating fractional anisotropy characteristics. AJNR Am J Neuroradiol. 2011;32:374-381. PŘEDNÁŠKY RS a menopauza – prof. MUDr. Eva Kubala Havrdová, CSc. Těhotenství a kojení u pacientů s RS – MUDr. Pavel Hradílek, Ph.D. Autoimunity u RS pacientů z pohledu imunologa – prof. RNDr. Jan Krejsek, CSc. Biologická léčba komorbidit u RS – onkologie – prof. MUDr. Petra Tesařová, CSc. ODBORNÝ GARANT prof. MUDr. Eva Kubala Havrdová, CSc. Neurologická klinika VFN a 1. LF UK v Praze PARTNER POČET KREDITŮ 2 Registrace ZDARMA TERMÍN prosinec 2022 až listopad 2023 dostupný na online.solen.cz On-line kurz pro praktické neurology Léčba pacienta s RS v průběhu dekád života 2 2022 ON LINE KURZ
RkJQdWJsaXNoZXIy NDA4Mjc=